5-溴-2-氟肉桂酸 | 202865-71-2

• 物质功能分类: 香精与香料 - 合成香料 - 芳香肉桂酸、酯及衍生物
• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 中文名称: 5-溴-2-氟肉桂酸
• 英文名称: 5-bromo-2-fluorocinnamic acid
• 英文别名: 3-(5-bromo-2-fluorophenyl)acrylic acid；3-(5-Bromo-2-fluoro-phenyl)-acrylic acid；3-(5-bromo-2-fluorophenyl)prop-2-enoic acid
• CAS: 202865-71-2
• 化学式: C₉H₆BrFO₂
• mdl: MFCD00143427
• 分子量: 245.048
• InChiKey: ROTBALNVXDGIQY-UHFFFAOYSA-N

物化性质

• 熔点：
  195-199 °C
• 沸点：
  336.0±32.0 °C(Predicted)
• 密度：
  1.6228 (rough estimate)
• 稳定性/保质期：
  避氧化物

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  2916399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Version 1.3
Regulation (EC) No 1907/2006

---

1 - Product and Company Information

---

Product Name 5-BROMO-2-FLUOROCINNAMIC ACID, 95%

---

2 - Hazards Identification

---

3 - Composition/Information on Ingredients

---

Product Name CAS # EC no Annex I
Index Number
5-BROMO-2-FLUOROCINNAMIC ACID 202865-71-2 None None
Formula C9H6BrFO2
Molecular Weight 245,0500 AMU

---

4 - First Aid Measures

---

AFTER INHALATION
If inhaled, remove to fresh air. If not breathing give
artificial respiration. If breathing is difficult, give oxygen.
AFTER SKIN CONTACT
In case of contact, immediately wash skin with soap and copious
amounts of water.
AFTER EYE CONTACT
In case of contact, immediately flush eyes with copious amounts
of water for at least 15 minutes.
AFTER INGESTION
If swallowed, wash out mouth with water provided person is
conscious. Call a physician.

---

5 - Fire Fighting Measures

---

EXTINGUISHING MEDIA
Suitable: Water spray. Carbon dioxide, dry chemical powder, or
appropriate foam.
ALDRICH www.molbase.com
SPECIAL RISKS
Specific Hazard(s): Emits toxic fumes under fire conditions.
SPECIAL PROTECTIVE EQUIPMENT FOR FIREFIGHTERS
Wear self-contained breathing apparatus and protective clothing
to prevent contact with skin and eyes.

---

6 - Accidental Release Measures

---

PROCEDURE(S) OF PERSONAL PRECAUTION(S)
Wear respirator, chemical safety goggles, rubber boots, and
heavy rubber gloves.
METHODS FOR CLEANING UP
Sweep up, place in a bag and hold for waste disposal. Avoid
raising dust. Ventilate area and wash spill site after material
pickup is complete.

---

7 - Handling and Storage

---

HANDLING
Directions for Safe Handling: Avoid inhalation. Avoid contact
with eyes, skin, and clothing. Avoid prolonged or repeated
exposure.
STORAGE
Conditions of Storage: Keep tightly closed. Store in a cool dry
place.

---

8 - Exposure Controls / Personal Protection

---

ENGINEERING CONTROLS
Safety shower and eye bath. Mechanical exhaust required.
GENERAL HYGIENE MEASURES
Wash thoroughly after handling. Wash contaminated clothing before
reuse.
PERSONAL PROTECTIVE EQUIPMENT
Respiratory Protection: Use respirators and components tested and
approved under appropriate government standards such as NIOSH (US)
or CEN (EU). Respiratory protection is not required. Where
protection is desired, use multi-purpose combination (US) or type
ABEK (EN 14387) respirator cartridges.
Hand Protection: Compatible chemical-resistant gloves.
Eye Protection: Chemical safety goggles.

---

9 - Physical and Chemical Properties

---

pH N/A
BP/BP Range N/A
MP/MP Range 192,000. - 196,000 °
C.
Flash Point N/A
Flammability N/A
Autoignition Temp N/A
Oxidizing Properties N/A
Explosive Properties N/A
Explosion Limits N/A
Vapor Pressure N/A
ALDRICH www.molbase.com
Partition Coefficient N/A
Viscosity N/A
Vapor Density N/A
Saturated Vapor Conc. N/A
Evaporation Rate N/A
Bulk Density N/A
Decomposition Temp. N/A
Solvent Content N/A
Water Content N/A
Surface Tension N/A
Conductivity N/A
Miscellaneous Data N/A
Solubility N/A

---

10 - Stability and Reactivity

---

STABILITY
Materials to Avoid: Strong oxidizing agents.
HAZARDOUS DECOMPOSITION PRODUCTS
Hazardous Decomposition Products: Carbon monoxide, Carbon dioxide,
Hydrogen fluoride, Hydrogen bromide gas.

---

11 - Toxicological Information

---

SIGNS AND SYMPTOMS OF EXPOSURE
To the best of our knowledge, the chemical, physical, and
toxicological properties have not been thoroughly investigated.
ROUTE OF EXPOSURE
Skin Contact: May cause skin irritation.
Eye Contact: May cause eye irritation.
Inhalation: Material may be irritating to mucous membranes and
upper respiratory tract.
Multiple Routes: May be harmful by inhalation, ingestion, or
skin absorption.

---

12 - Ecological Information

---

No data available.

---

13 - Disposal Considerations

---

SUBSTANCE DISPOSAL
Dissolve or mix the material with a combustible solvent and burn
in a chemical incinerator equipped with an afterburner and
scrubber. Observe all federal, state, and local environmental
regulations.

---

14 - Transport Information

---

RID/ADR
Non-hazardous for road transport.
IMDG
Non-hazardous for sea transport.
IATA
Non-hazardous for air transport.

---

ALDRICH www.molbase.com
15 - Regulatory Information

---

Caution: Substance not yet fully tested (EU).
COUNTRY SPECIFIC INFORMATION
Germany
WGK: 3
Self-Classification

---

16 - Other Information

---

WARRANTY
The above information is believed to be correct but does not
purport to be all inclusive and shall be used only as a guide. The
information in this document is based on the present state of our
knowledge and is applicable to the product with regard to
appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Inc.,
shall not be held liable for any damage resulting from handling or
from contact with the above product. See reverse side of invoice
or packing slip for additional terms and conditions of sale.
Copyright 2010 Co. License granted to make
unlimitedpaper copies for internal use only.
DISCLAIMER
For R&D use only. Not for drug, household or other uses.
ALDRICH www.molbase.com

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-溴-2-氟肉桂酸 在 tris-(dibenzylideneacetone)dipalladium(0) 、 硼烷四氢呋喃络合物 、 potassium tert-butylate 、 氢气 、 甲烷 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 sulfur 、 N,N-二异丙基乙胺 、 铂 、 2-二环己基磷-2,4,6-三异丙基联苯 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 叔丁醇 为溶剂， 反应 23.0h， 生成 9-chloro-2-({3-[3-(dimethylamino)propyl]-4-fluorophenyl}amino)-5,7-dihydro-6H-pyrimido[5,4-d][1]benzazepin-6-one
  参考文献：
  名称：

  Discovery of a Potent and Orally Bioavailable Benzolactam-Derived Inhibitor of Polo-Like Kinase 1 (MLN0905)

  摘要：

  This article describes the discovery of a series of potent inhibitors of Polo-like kinase 1 (PLK1). Optimization of this benzolactam-derived chemical series produced an orally bioavailable inhibitor of PLK1 (12c, MLN0905). In vivo pharmacokinetic-pharmacodynamic experiments demonstrated prolonged mitotic arrest after oral administration of 12c to tumor bearing nude mice. A subsequent efficacy study in nude mice achieved tumor growth inhibition or regression in a human colon tumor (HT29) xenograft model.

  DOI：

  10.1021/jm2011172
• 作为产物：
  描述：

  丙二酸 、 5-溴-2-氟苯甲醛 在 哌啶 、 吡啶 作用下， 生成 5-溴-2-氟肉桂酸
  参考文献：
  名称：

  Rh(I)-催化不对称 C-H 芳基化的明确机理及平面手性二茂铁的简便合成

  摘要：

  机理引导的反应开发是化学中广受认可的研究范式，因为机理知识的融合将加速新合成方法的发现。低价过渡金属如 Pd(0)- 和 Rh(I)- 催化的 C-H 与芳基（假）卤化物的芳基化反应是两种不同芳基伙伴的排他性交叉偶联的促成反应。然而，与 Pd(0) 催化的情况不同，Rh(I) 催化的 C-H 芳基化的机理尚未得到充分探索。芳基 C-H 活化和芳基（假）卤化物的氧化加成的基本步骤的顺序仍不清楚。在此，我们报告了对 Rh(I) 催化的 2-吡啶基二茂铁和芳基溴化物之间的分子间不对称 C-H 芳基化的明确机制理解的综合实验和计算研究。催化循环中每个基本步骤的识别以及关键中间体和过渡态的结构表征允许合理设计和开发具有挑战性的分子内反应。该反应模式的成功实现为平面手性分子的简便合成奠定了基础[m ]ferrocenophanes ( m = 6–8)，一类很少探索的目标分子，具有应变结构和有趣的分子拓扑结构。

  DOI：

  10.1021/jacs.2c13542

文献信息

• 4,5-DIHYDRO-1H-PYRAZOLE DERIVATIVE OR SALTS THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
  申请人：YUHAN CORPORATION

  公开号：US20150291563A1

  公开（公告）日：2015-10-15

  The present invention provides a 4,5-dihydro-1H-pyrazole derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, and a pharmaceutical composition comprising the same. The 4,5-dihydro-1H-pyrazole derivative or its pharmaceutically acceptable salt effectively increases the LXR transcriptional activity, and therefore can be usefully applied for preventing or treating a dysfunction in cholesterol metabolism, such as cholesterol gallstone, hyperlipidemia, or coronary atherosclerosis.

  本发明提供了一种4,5-二氢-1H-吡唑烷衍生物或其药用可接受盐，以及其制备方法和包含该衍生物的药物组合物。4,5-二氢-1H-吡唑烷衍生物或其药用可接受盐有效增加LXR转录活性，因此可以有效地用于预防或治疗胆固醇代谢功能障碍，如胆固醇结石、高脂血症或冠状动脉粥样硬化。
• Substituted azole derivatives as therapeutic agents
  申请人：——

  公开号：US20040192743A1

  公开（公告）日：2004-09-30

  This invention provides azoles which may be useful as inhibitors of protein tyrosine phosphatases (PTPases). The present invention provides compounds of Formula (I), methods of their preparation, pharmaceutical compositions comprising the compounds and their use in treating human or animal disorders. The compounds of the invention may be useful as inhibitors of protein tyrosine phosphatases and thus can be useful for the management, treatment, control and adjunct treatment of diseases mediated by PTPase activity. Such diseases include Type I diabetes, Type II diabetes.

  这项发明提供了一些可能作为蛋白酪氨酸磷酸酶（PTPases）抑制剂有用的唑类化合物。本发明提供了式（I）的化合物，它们的制备方法，包含这些化合物的制药组合物以及它们在治疗人类或动物疾病中的应用。本发明的化合物可能作为蛋白酪氨酸磷酸酶的抑制剂有用，因此可用于管理、治疗、控制和辅助治疗由PTPase活性介导的疾病，如1型糖尿病、2型糖尿病等。
• Oxazolidinone combinatorial libraries, compositions and methods of preparation
  申请人：Gordeev F. Mikhail

  公开号：US20050004174A1

  公开（公告）日：2005-01-06

  Oxazolidinones and methods for their synthesis are provided. Also provided are combinatorial libraries comprising oxazolidinones, and methods to prepare the libraries. Further provided are methods of making biologically active oxazolidinones as well as pharmaceutically acceptable compositions comprising the oxazolidinones. The methods of library preparation include the attachment of oxazolidinones to a solid support. The methods of compound preparation in one embodiment involve the reaction of an iminophosphorane with a carbonyl containing polymeric support.

  本发明提供了氧杂环丙烷酮及其合成方法。还提供了包含氧杂环丙烷酮的组合化学文库以及制备这些文库的方法。此外，还提供了制备生物活性氧杂环丙烷酮的方法以及包含氧杂环丙烷酮的药学可接受组合物的方法。文库制备的方法包括将氧杂环丙烷酮附着到固体支持上。在一种实施例中，化合物制备的方法涉及将亚胺磷酰胺与含有羰基的聚合物支持物反应。
• Sulfonium salt compound
  申请人：——

  公开号：US20040033434A1

  公开（公告）日：2004-02-19

  A compound shown by the general formula [1] 1 (wherein R 1 , R 2 and R 3 are each independently an aromatic hydrocarbon residual group, Y n− is an anion derived from a carboxylic acid having 3 or more carbon atoms with substituted fluorine atoms, and n is 1 or 2, provided that R 1 , R 2 and R 3 each is not a phenyl group having substituents at an ortho and/or a meta position), and a composition consisting of the compound and a diazodisulfone compound are disclosed. Use of the compound or the compound as an acid generator for resists produces the effects of improving the profiles of ultra-fine patterns or diminishing sidewall irregularities in ultra-fine patterns. The compound is also useful as a cationic photopolymerization initiator.

  公式为[1]1的化合物被展示出来（其中R1、R2和R3各自独立地是芳香族碳氢残基，Yn−是源自具有3个或更多碳原子的羧酸的阴离子，其中含有取代的氟原子，n为1或2，前提是R1、R2和R3各自不是具有取代基的苯基，该取代基位于邻位和/或间位），并且由该化合物和一种二硫酰二氮化合物组成的组合物被公开。使用该化合物或该化合物作为酸发生剂用于光刻胶会产生改善超细图案轮廓或减少超细图案侧壁不规则性的效果。该化合物还可用作阳离子光聚合引发剂。
• Substituted Azole Derivatives as Therapeutic Agents
  申请人：Mjalli Adnan M. M.

  公开号：US20110077399A1

  公开（公告）日：2011-03-31

  This invention provides azoles which may be useful as inhibitors of protein tyrosine phosphatases (PTPases). The present invention provides compounds of Formula (I), methods of their preparation, pharmaceutical compositions comprising the compounds and their use in treating human or animal disorders. The compounds of the invention may be useful as inhibitors of protein tyrosine phosphatases and thus can be useful for the management, treatment, control and adjunct treatment of diseases mediated by PTPase activity. Such diseases include Type I diabetes, Type II diabetes.

  本发明提供了一些可能用作蛋白酪氨酸磷酸酶（PTPases）抑制剂的唑类化合物。本发明提供了式（I）的化合物，它们的制备方法，包含这些化合物的药物组合物以及它们在治疗人类或动物疾病方面的用途。本发明的化合物可能有用作蛋白酪氨酸磷酸酶的抑制剂，因此可以用于管理、治疗、控制和辅助治疗由PTPase活性介导的疾病，例如1型糖尿病、2型糖尿病。